StockNews.AI
HAE
StockNews.AI
141 days

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

1. Haemonetics will announce Q4 and FY2025 results on May 8, 2025. 2. A conference call with investors will follow the results announcement. 3. Company focuses on innovative medical products to improve patient care.

Earnings
-0.83%Current Return
VS
+0.32%S&P 500
$63.5503/31 04:23 PM EDTEvent Start
$63.0204/01 10:57 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

The upcoming results may confirm existing trends without major surprises, similar to prior earnings announcements which showed moderate growth.

How important is it?

Earnings reports often dictate short-term market movements; however, the context of reported results is crucial.

Why Short Term?

Investor reactions to upcoming earnings results will affect price, as seen in previous quarters.

Related Companies

NYSE: HAENYSE: ABTNYSE: VAR
, /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. The call can be accessed via teleconference at: Q4 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start. A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/4z9yixt9  A replay of the conference call and webcast will be available for one year beginning on May 8, 2025 at 11:00 am ET using the conference call webcast link provided in this press release.ABOUT HAEMONETICSHaemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com. Investor Contacts: Olga Guyette, Vice President-Investor Relations & Treasury David Trenk, Manager-Investor Relations (781) 356-9763 (203) 733-4987 [email protected] [email protected]  Media Contact: Josh Gitelson, Sr. Director-Global Communications (781) 356-9776 [email protected] SOURCE Haemonetics Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News